Adaptive Randomization:

Size: px
Start display at page:

Download "Adaptive Randomization:"

Transcription

1 : Promise with Problems Russell W. Helms, Ph.D. Rho, Inc. Chapel Hill, NC Presented to The Annual DIA Workshop on Statistical Methodology in the Biopharmaceutical Sciences Philadelphia, PA 03 March 2004 Before we get started: STAT SIAC SIAC: Special Interest Area Community DIA reorganizing: grassroots Newly functioning Needs Assessment Volunteers? Website, newsletter, networking, programming, training Talk to me! me: DIA Copyright 2004 Rho, Inc. 2 : Promise with Problems Agenda Introduction: What and Why? Types of and Inference Advice: What (not) to Do in Practice Conclusions Special Thanks Rosenberger and Lachin (2002) McEntegart (2003 DIJ) : What & Why? What is randomization? The act of assigning treatments to observational units using (an element of) chance. and why do we do it? two adequate and well controlled studies RCT is the gold standard Control bias, basis for inference is necessary to control bias, but not sufficient Related topics: controls, masking Copyright 2004 Rho, Inc. 3 Copyright 2004 Rho, Inc. 4 Controls: What & Why? Masking: What & Why? Now a gold standard, but Salk: I found but one person who rigidly adhered to the idea of a placebo control and he is a bio-statistician who, if he did not adhere to this view, would have had to admit his own purposelessness in life. FDA helps Placebo effect, paper challenging it Better than what? New information is obtained from a comparison of alternate states Association and causation Masking = Blinding = Veiling Masking helps control sources of bias Selection bias: investigators may be able to bias composition of treatment groups by choosing (not) to enroll based on what treatment a particular patient may receive Subconscious preference more likely than deliberate dishonesty e.g., Good prognosis versus bad prognosis e.g., Likely to respond to this treatment Worse: investigators (or subjects) may grade outcomes differently Eliminates placebo effect? Copyright 2004 Rho, Inc. 5 Copyright 2004 Rho, Inc. 6

2 Masking: What & Why? Masking is not always possible. Emergency unmasking Surgery (Story: arthroscopic surgery trial for osteoarthritis) Even when planned, patients and investigators are smart, and discern. Side effects, lab tests, response (Story: Good Friday experiment) Plenty of examples in literature, my experience Implication on randomization and guessing : What & Why? Why random allocation? 1:Control Bias (throughout) e.g., selection bias Story: Teachers switching treatment groups From Chalmers et al., 1977: 32 Studies of anticoagulants for acute MI. Mortality improvement in: 15/18 studies using historical controls (900 pts), 5/8 studies using nonrandomized concurrent controls (3,000 pts).» Pooled: 50% reduction in mortality 1/6 RCT (3,800 pts).» Pooled: 20% reduction in mortality Bias > effect? Large effect versus small effect: Other publications show examples of inappropriately favoring new interventions Copyright 2004 Rho, Inc. 7 Copyright 2004 Rho, Inc. 8 : What & Why? : What & Why? Why random allocation? 1:Control Bias (throughout) e.g., accidental bias from covariates/confounders. Imbalance of important prognostic factors basic problem of observational studies e.g., Smoking and Lung Cancer (Fisher) Story: NCI HIP RCT: PE + Mammography recommendations lowered breast cancer mortality. But within test group, those who refused exam had lower breast cancer mortality.» Self-selection confounding by education level. tends to produce comparable groups: both measured and unknown prognostic factors. Size and direction of imbalances distributed over trials Small trials may have imbalances Leap from association to causation Why random allocation? 2:Basis for inference (section later) Issues specific to RCT in Drug Development Sequential appearance of potential subjects Inclusion/Exclusion criteria Multicenter trials Phases with different goals Implemented by very intelligent people Implemented by people with (sometimes poor) judgment Story: investigator too busy to call CIRS Rescue Story: investigators forgot ==> multiple randomizations Studying people with independent will: plan for some chaos Copyright 2004 Rho, Inc. 9 Copyright 2004 Rho, Inc. 10 : What & Why? Four Types of Given (what I ve just explained about) why we randomize, what do we seek in a randomization? Control bias (selection, accidental, etc.), basis for inference Stochastic versus deterministic e.g., alternating sequence (ABAB, BABA ) isn t randomization ICH E9: random element in all assignments What does adaptive mean? At simplest level, one treatment assignment is at least partially dependent on another Strict definition: can t generate a complete schedule before the first patient is randomized Complete randomization Simple coin tossing Restricted randomization (e.g., permuted blocks) Complex coin tossing: add restrictions on the coin and how it is used to ensure balance of treatment arms Covariate-adaptive randomization (e.g., Pocock and Simon) Used to ensure balance of treatment arms with respect to certain known covariates Response-adaptive randomization Treatment assignments depend upon previous patient responses Copyright 2004 Rho, Inc. 11 Copyright 2004 Rho, Inc. 12

3 Types of : Complete Complete randomization Simple coin tossing Not adaptive No selection bias: impossible to predict Chance of (possibly severe) treatment imbalance: one treatment may be assigned more frequently than another at any point in the trial, including the end. Why want equal (balanced) allocation? Max power: generally not much of an issue, but extreme imbalances, while rare, can be a serious problem. (Seek balance for insurance.) Equipoise and ethics Facilitates CTM supply management Chronological bias: patients differ over time of enrollment e.g., epidemics in vaccine or anti-infective trials Types of : Restricted Restricted randomization Complex coin tossing: add restrictions on the coin and how it is used to ensure balanced allocation of treatments. Very common. Different assignments are somewhat dependent: Adaptive at simplest level, but not by strict definition Examples: Random Allocation Rule: Urn drawing without replacement. Avoid because: Deterministic in late stages: selection bias, chronological bias, inference Truncated Binomial design Binomial until one treatment group full. Avoid because: Deterministic in late stages: selection bias, chronological bias, inference Possibility of severe covariate imbalances and resulting accidental bias Permuted blocks (more on next page) Copyright 2004 Rho, Inc. 13 Copyright 2004 Rho, Inc. 14 Types of : Restricted Permuted Block design: most common in our industry Promise: Balance at end and throughout: every n-th subject. [BABA] [AABB] [ABAB] Important when: time-heterogenous covariate related to treatment outcome: avoid chronological bias interim analyses are planned The trial might be stopped early. Problems: Overall imbalance possible with incomplete blocks inference and wasted data (more later) Large element of determinism (every block) selection bias: secret and/or variable block size (worse?) determinism and inference (potentially small reference set) Types of : Restricted (Generalized) Biased Coin Designs Examples Effron s Biased Coin design Vary p from ½ when balance gets bad Only two values of p (1/2 or other) Some more deterministic modifications aim to prevent extreme imbalance Wei s Urn design Adaptive biased coin design: p varies by degree of imbalance Urn with replacement plus a few Promise: balance, difficult to predict (selection bias) Problems: analysis complications, chronological bias Copyright 2004 Rho, Inc. 15 Copyright 2004 Rho, Inc. 16 Types of : Restricted Maximal Procedure (Berger, Ivanova, Knoll, 2003) Relatively new, relatively untried Maximal reference set subject to maximum tolerated imbalance condition Focus on terminal balance, maximum tolerated imbalance, and ignore forced returns to exact balance (as in permuted blocks) Can implement with complete randomization and replacement randomization (discarding sequences that don t fit constraints) Promise: controls balance (chronological bias), difficult to predict (selection bias), not necessarily deterministic Problems: untested, explaining to investigators, IRBs, etc. Types of : Restricted Restricted randomization summary: Complex coin tossing: add restrictions on the coin and how it is used to ensure balanced allocation of treatments. Different assignments are somewhat dependent: Adaptive at simplest level, but not by strict definition Permuted blocks is the most common, maximal procedure may be better Copyright 2004 Rho, Inc. 17 Copyright 2004 Rho, Inc. 18

4 Types of : Covariate- Often covariates or prognostic factors of interest besides treatment affect outcome. e.g., site in a multi-center trial is often the greatest source of variability e.g., infections: nosocomial versus community-acquired, resistant versus not e.g., baseline severity of disease Arthritis examples: Duration of illness: 2-3 years versus 10+ years (potentially continuous) Prior treatment history Accidental bias may result from imbalances on such factors. Especially true for permuted block randomization, as the asymptotic decline of accidental bias is slow for that design (Rosenberger and Lachin) Types of : Covariate- Covariates besides treatment affect outcome: Solution 1: Stratification = Separate randomization for each level of factor, with any randomization method so far discussed. Promise: stratification can protect from accidental bias (known covariates + correlates) and also increase power. Note: stratification on randomization requires stratification in analysis; stratification in analysis is possible without stratification in randomization, similar power gains Problems: treatment balance within strata may reduce overall balance Number of strata increases rapidly and can make overall balance impossible Copyright 2004 Rho, Inc. 19 Copyright 2004 Rho, Inc. 20 Types of : Covariate- Covariates besides treatment affect outcome: Solution 2: Covariate-adaptive randomization of subject # (k+1) depends on balance among first k subjects, assign k+1 the treatment that minimizes the imbalance Zelen s Rule: Use schedule but swap when balance bad Wei s marginal Urn design: similar to urn design with urns for margins of covariates, instead of an urn for each stratum Optimal Design: Based on linear model, minimize variance of estimated treatment effect in presence of covariates. Note different than balancing over covariates to mitigate bias. Difficult to implement and to explain to nonstatisticians. Types of : Covariate- Pocock and Simon (sometimes called minimization ) Independent generalization of Taves; incorporates stochastic element. Measures imbalance on each factor then combines to get an overall measure of imbalance associated with each treatment. Bad imbalance implies a high probability (e.g., biased coin) of assigning a treatment. Tip: Unlike stratification, can account for many levels of strata. Metrics are arbitrary, but intuitive. Little research on properties, but used with some frequency. Tip: simulation to discern properties for each implementation Tip: Balances margins, not cells. Series of adaptations: Begg & Iglewicz, Atkinson, Frane (lead to Optimal ) Story: Site-level imbalance in anti-infective. Tip: Imbalance measure based on variance better than based on range: better avoid extreme imbalances Tip: Include factors in analysis Copyright 2004 Rho, Inc. 21 Copyright 2004 Rho, Inc. 22 Types of : Covariate- Promise: Insurance: extreme covariate imbalance; while unlikely, may make a trial difficult/impossible to interpret. Enhances credibility for less statistically sophisticated reviewers who may misunderstand or mistrust model-based adjustments for imbalance Increases precision and interpretability for interim analyses and early-stopped trials Avoids analysis problems of empty cells, and Handles very many factor levels Types of : Covariate- Problems: Implementation, analysis can be complicated (inference) Possibility of selection bias increases as p 1 Intuitive method, properties not (yet) fully explored Doesn t guarantee balance of unmeasured covariates (accidental bias), though simulation studies suggest it may help (Rosenberger & Lachin) Balance may be overrated Copyright 2004 Rho, Inc. 23 Copyright 2004 Rho, Inc. 24

5 Types of : Covariate- In general, The more stochastic, the better ICH E9 Guidance: Use random element in all assignments. Forcing treatment balance among covariates may be overrated: be quite sure it s necessary before stratifying or implementing covariate-adaptive procedure. EXCEPTION: Site Many cells: stick with modified P&S: stochastic (e.g., p=0.8) great balance and difficult to predict, but unknown properties Comparison to permuted block design: P&S less chance of selection bias as long as p < 1 P&S less deterministic as long as p < 1 P&S may be better at preventing accidental, chronological bias Types of : Response- Treatment assignments depend upon previous patient responses, e.g., Play-the-winner : highly deterministic Two-armed bandit : more like generalized biased coin Promise: Ethics: maximize number of patients on superior treatment Problems: Requires rapid ascertainment of patient outcomes Lower power (larger sample size offsets ethical advantage) Chronological bias. Story: ECMO example (1 F, 9S, Stop) Analysis complicated: inference next slide! Comment: Other CT designs (NonStop designs, interim analyses) can accomplish similar goals Copyright 2004 Rho, Inc. 25 Copyright 2004 Rho, Inc. 26 and Inference and Inference: Population Model A goal of randomization is to aid in inference from the trial. Two methods: Population-Model Tests Editorial: Practical, simulation-supported hand-waving Permutation Tests ( model) Editorial: Mathematically rigorous complications Population A: Y ~ G(y θ A ) Sample at Random n A Subjects: Y Aj ~ G(y θ A ) Population B: Y ~ G(y θ B ) Sample at Random n A Subjects: Y Bj ~ G(y θ B ) H 0 : θ A = θ B Note: Adapted from (Lachin, 1988) Copyright 2004 Rho, Inc. 27 Copyright 2004 Rho, Inc. 28 and Inference: Model n eligible & consenting subjects, presenting sequentially n A subjects n B subjects H 0 :Outcomes evenly distributed among n A, n B Note: Adapted from (Lachin, 1988) Copyright 2004 Rho, Inc. 29 and Inference: Approaches address different questions (null hypotheses). Permutation: Probability that observed effect (or more) in n patients actually randomized into the trial could have occurred by chance Allows conclusions about effects of treatment in patients actually studied. Population: Probability that at the observed effect (or more) in n patients studied could have been observed in samples of n A and n B drawn at random from respective populations. Allows conclusions about effects of treatment in hypothesized general population. Thus generalization may be different, but this is really a bigger issue of trial design (inclusion/exclusion criteria, etc.) Copyright 2004 Rho, Inc. 30

6 and Inference: Approaches address design differently: Permutation tests: assumes outcomes fixed, treatment assignment is a random variable Population model: treatment (populations) fixed, outcome is a random variable Approaches have different assumptions: Permutation tests require virtually no assumptions. Population model requires faith in untestable assumptions. Population model based on Neyman-Pearson. Type of randomization matters for permutation tests, but is ignorable for population This bothers some in the strict analyze as randomize crowd. Power and sample size must be based on population Sometimes permutation test wastes data e.g., unfilled blocks Copyright 2004 Rho, Inc. 31 and Inference: For complete randomization, the approaches produce the same statistic. Not true for restricted or adaptive. In practice, a variety of authors have concluded it is rare to get a substantially different answer from the approaches. Population-model may be slightly conservative, but permutation test has discrete p-values. Be careful with the reference set! (At least 20 members ) No difference strict adaptive versus not: any dependency of treatment assignments makes the two approaches different. Decide whether or not you believe the population model assumptions. Apply this decision consistently: including permuted block Don t forget blocking factor in analysis, or the test is conservative. Choice of randomization details shouldn t influence inference preference Inference preference may influence randomization method Copyright 2004 Rho, Inc. 32 and Inference: Beware chaos and extreme complications: permutation tests can make our job interesting and exciting! Story: ice storm Remember other stories Interim analyses, stratification Permutation tests may be more appealing to statisticians. Theoretically sound, intuitive. Fun to program! Out-of-context Salk quotation from earlier: and he is a bio-statistician who, if he did not adhere to this view, would have had to admit his own purposelessness in life. Population tests may be more intuitive to non-statisticians. Beware inflicting our purpose in life on others needlessly. Recommendations: What (not) to Do should be stochastic, not deterministic (ICH E9). Mask vigorously. Mask all details, including block sizes, parameter values Stratification: Stratify on center (ICH E9) Keep it simple, adjust in analysis (Post-adjust whether or not pre-adjust) If you can t keep it simple, use Pocock and Simon instead. Worry more about selection bias than balance, especially when balancing covariates. Copyright 2004 Rho, Inc. 33 Copyright 2004 Rho, Inc. 34 Recommendations: What (not) to Do Rosenberger s and Lachin s recommendation: two stage inference: Tests are permutation tests Estimates based on population model My recommendation: Use population model through Phase-II. Before Phase-III, ask FDA. If permutation test is possible, be wary of the size of the reference set: don t use a design whose minimum p-value is > 0.05! Conclusions Promise? Bias control and inference. Problems? Bias control and inference. In practice, nearly all randomization designs are adaptive in the simplest sense: one treatment assignment is at least partially dependent on another. Permuted block designs, while common, suffer from many of the same problems as more adaptive designs. Adopt a method of inference faithfully regardless of randomization details. Have faith? Either you believe the population model or you don t. Population Model Analysis is independent of randomization details; Permutation Test Analysis depends on them absolutely. Permutation tests can be complicated, especially with chaos. Controlling selection bias is paramount. Copyright 2004 Rho, Inc. 35 Copyright 2004 Rho, Inc. 36

7 Conclusions The Powerpoint presentation will be available on the internet: questions, comments, etc. to: UNIX types: you don t have to use capital letters Thank you! Copyright 2004 Rho, Inc. 37

Issues to Consider in the Design of Randomized Controlled Trials

Issues to Consider in the Design of Randomized Controlled Trials Issues to Consider in the Design of Randomized Controlled Trials Jay Wilkinson, MD, MPH Professor of Pediatrics & Epidemiology Miller School of Medicine Seminar Purpose To facilitate an interactive discussion

More information

Randomization: Too Important to Gamble with

Randomization: Too Important to Gamble with Randomization: Too Important to Gamble with A Presentation for the Delaware Chapter of the ASA Oct 18, 2012 Dennis Sweitzer, Ph.D., Principal Biostatistician Medidata Randomization Center of Excellence

More information

Statistics for Clinical Trials: Basics of Phase III Trial Design

Statistics for Clinical Trials: Basics of Phase III Trial Design Statistics for Clinical Trials: Basics of Phase III Trial Design Gary M. Clark, Ph.D. Vice President Biostatistics & Data Management Array BioPharma Inc. Boulder, Colorado USA NCIC Clinical Trials Group

More information

Issues in Randomization

Issues in Randomization INTRODUCTION TO THE PRINCIPLES AND PRACTICE OF CLINICAL RESEARCH Issues in Randomization Paul Wakim, PhD Chief, Biostatistics and Clinical Epidemiology Service Clinical Center, National Institutes of Health

More information

In this second module in the clinical trials series, we will focus on design considerations for Phase III clinical trials. Phase III clinical trials

In this second module in the clinical trials series, we will focus on design considerations for Phase III clinical trials. Phase III clinical trials In this second module in the clinical trials series, we will focus on design considerations for Phase III clinical trials. Phase III clinical trials are comparative, large scale studies that typically

More information

PhD Course in Biostatistics

PhD Course in Biostatistics PhD Course in Biostatistics Univ.-Prof. DI Dr. Andrea Berghold Institute for Medical Informatics, Statistics and Documentation Medical University of Graz andrea.berghold@medunigraz.at Content Introduction

More information

Phase III Clinical Trial. Randomization, Blinding and Baseline Assessment. Chi-hong Tseng, PhD Statistics Core, Department of Medicine

Phase III Clinical Trial. Randomization, Blinding and Baseline Assessment. Chi-hong Tseng, PhD Statistics Core, Department of Medicine Phase III Clinical Trial Randomization, Blinding and Baseline Assessment Chi-hong Tseng, PhD Statistics Core, Department of Medicine Reference Clinical Trials: A Practical Approach. Pocock SJ. Wiley, Chichester,

More information

Lecture 2. Key Concepts in Clinical Research

Lecture 2. Key Concepts in Clinical Research Lecture 2 Key Concepts in Clinical Research Outline Key Statistical Concepts Bias and Variability Type I Error and Power Confounding and Interaction Statistical Difference vs Clinical Difference One-sided

More information

Greg Pond Ph.D., P.Stat.

Greg Pond Ph.D., P.Stat. Statistics for Clinical Trials: Basics of a Phase III Trial Design Greg Pond Ph.D., P.Stat. Ontario Clinical Oncology Group Escarpment Cancer Research Institute Department of Oncology, McMaster University

More information

CHL 5225 H Advanced Statistical Methods for Clinical Trials. CHL 5225 H The Language of Clinical Trials

CHL 5225 H Advanced Statistical Methods for Clinical Trials. CHL 5225 H The Language of Clinical Trials CHL 5225 H Advanced Statistical Methods for Clinical Trials Two sources for course material 1. Electronic blackboard required readings 2. www.andywillan.com/chl5225h code of conduct course outline schedule

More information

RANDOMIZATION. Outline of Talk

RANDOMIZATION. Outline of Talk RANDOMIZATION Basic Ideas and Insights Marvin Zelen Harvard University Graybill Conference Ft.Collins, Colorado June 11, 2008 Outline of Talk Introduction Randomized vs. Observational Studies Conditioning

More information

Chapter 5: Producing Data

Chapter 5: Producing Data Chapter 5: Producing Data Key Vocabulary: observational study vs. experiment confounded variables population vs. sample sampling vs. census sample design voluntary response sampling convenience sampling

More information

Fundamental Clinical Trial Design

Fundamental Clinical Trial Design Design, Monitoring, and Analysis of Clinical Trials Session 1 Overview and Introduction Overview Scott S. Emerson, M.D., Ph.D. Professor of Biostatistics, University of Washington February 17-19, 2003

More information

Randomization and Randomized Control Trial

Randomization and Randomized Control Trial Review Article Accepted on: 31-12-2012; Finalized on: 28-02-2013. ABSTRACT Randomization and Randomized Control Trial Ashutosh Derashri*, Noopur Suba Ahmedabad, Gujarat, India. *Corresponding author s

More information

Comments on the Controversy over Response-Adaptive Randomization

Comments on the Controversy over Response-Adaptive Randomization Comments on the Controversy over Response-Adaptive Randomization Rick Chappell, Ph.D. Professor, Department of Biostatistics and Medical Informatics The Paul P. Carbone Comprehensive Cancer Center University

More information

Bayesian and Frequentist Approaches

Bayesian and Frequentist Approaches Bayesian and Frequentist Approaches G. Jogesh Babu Penn State University http://sites.stat.psu.edu/ babu http://astrostatistics.psu.edu All models are wrong But some are useful George E. P. Box (son-in-law

More information

Randomized Controlled Trial

Randomized Controlled Trial Randomized Controlled Trial Training Course in Sexual and Reproductive Health Research Geneva 2016 Dr Khalifa Elmusharaf MBBS, PgDip, FRSPH, PHD Senior Lecturer in Public Health Graduate Entry Medical

More information

Sequence balance minimisation: minimising with unequal treatment allocations

Sequence balance minimisation: minimising with unequal treatment allocations Madurasinghe Trials (2017) 18:207 DOI 10.1186/s13063-017-1942-3 METHODOLOGY Open Access Sequence balance minimisation: minimising with unequal treatment allocations Vichithranie W. Madurasinghe Abstract

More information

Trick or Treat. In April!

Trick or Treat. In April! Trick or Treat. In April! Take one small envelope but Don t open it! Teaching and Leading EBM 2018 Randomization: simple, stratified and block Juan M. Lozano, MD, MSc Describe three methods of randomization:

More information

Dynamic Allocation Methods: Why the Controversy?

Dynamic Allocation Methods: Why the Controversy? Dynamic Allocation Methods: Why the Controversy? Greg Pond Ph.D., P.Stat. Ontario Clinical Oncology Group Department of Oncology Department of Clinical Epidemiology and Biostatistics 11 December 2009 TRENDS

More information

Design and analysis of clinical trials

Design and analysis of clinical trials Design and analysis of clinical trials Lecture 3 1.Basic Design Considerations 2.Sample Size determinationa 3.Randomization 2018-01-31 Previous Lectures Definition of a clinical trial The drug development

More information

Creating Comparable Comparison Groups in Randomized Clinical Trials. Vance W. Berger, NCI 10/25/16, BASS, Rockville

Creating Comparable Comparison Groups in Randomized Clinical Trials. Vance W. Berger, NCI 10/25/16, BASS, Rockville Creating Comparable Comparison Groups in Randomized Clinical Trials Vance W. Berger, NCI 10/25/16, BASS, Rockville Abstract Randomization is one of the cornerstones of the randomized clinical trial, and

More information

REVIEW FOR THE PREVIOUS LECTURE

REVIEW FOR THE PREVIOUS LECTURE Slide 2-1 Calculator: The same calculator policies as for the ACT hold for STT 315: http://www.actstudent.org/faq/answers/calculator.html. It is highly recommended that you have a TI-84, as this is the

More information

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POINTS TO CONSIDER ON MISSING DATA

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POINTS TO CONSIDER ON MISSING DATA The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 15 November 2001 CPMP/EWP/1776/99 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POINTS TO

More information

Placebo and Belief Effects: Optimal Design for Randomized Trials

Placebo and Belief Effects: Optimal Design for Randomized Trials Placebo and Belief Effects: Optimal Design for Randomized Trials Scott Ogawa & Ken Onishi 2 Department of Economics Northwestern University Abstract The mere possibility of receiving a placebo during a

More information

A Brief Introduction to Bayesian Statistics

A Brief Introduction to Bayesian Statistics A Brief Introduction to Statistics David Kaplan Department of Educational Psychology Methods for Social Policy Research and, Washington, DC 2017 1 / 37 The Reverend Thomas Bayes, 1701 1761 2 / 37 Pierre-Simon

More information

Accelerating Innovation in Statistical Design

Accelerating Innovation in Statistical Design Implementing a National Cancer Clinical Trials System for the 21 st Century, Workshop #2 Session #5: Accelerating Innovation Through Effective Partnerships Accelerating Innovation in Statistical Design

More information

CHAPTER 5: PRODUCING DATA

CHAPTER 5: PRODUCING DATA CHAPTER 5: PRODUCING DATA 5.1: Designing Samples Exploratory data analysis seeks to what data say by using: These conclusions apply only to the we examine. To answer questions about some of individuals

More information

e.com/watch?v=hz1f yhvojr4 e.com/watch?v=kmy xd6qeass

e.com/watch?v=hz1f yhvojr4   e.com/watch?v=kmy xd6qeass What you need to know before talking to your statistician about sample size Sharon D. Yeatts, Ph.D. Associate Professor of Biostatistics Data Coordination Unit Department of Public Health Sciences Medical

More information

研究設計理論 ( 一 ): RANDOMIZED TRIALS. 醫學研究初階課程 General Medicine, CGMH 劉素旬醫師 03/12/2013

研究設計理論 ( 一 ): RANDOMIZED TRIALS. 醫學研究初階課程 General Medicine, CGMH 劉素旬醫師 03/12/2013 1 研究設計理論 ( 一 ): RANDOMIZED TRIALS 醫學研究初階課程 General Medicine, CGMH 劉素旬醫師 03/12/2013 2 Learning Objectives Definition of a trial Features of trial design Elements of a trial Purposes of randomization and

More information

Applied Analysis of Variance and Experimental Design. Lukas Meier, Seminar für Statistik

Applied Analysis of Variance and Experimental Design. Lukas Meier, Seminar für Statistik Applied Analysis of Variance and Experimental Design Lukas Meier, Seminar für Statistik About Me Studied mathematics at ETH. Worked at the statistical consulting service and did a PhD in statistics (at

More information

Department of OUTCOMES RESEARCH

Department of OUTCOMES RESEARCH Department of OUTCOMES RESEARCH Clinical Research Design Sources of Error Types of Clinical Research Randomized Trials! Daniel I. Sessler, M.D. Professor and Chair Department of OUTCOMES RESEARCH The Cleveland

More information

Online Supplementary Material

Online Supplementary Material Section 1. Adapted Newcastle-Ottawa Scale The adaptation consisted of allowing case-control studies to earn a star when the case definition is based on record linkage, to liken the evaluation of case-control

More information

Designing Studies of Diagnostic Imaging

Designing Studies of Diagnostic Imaging Designing Studies of Diagnostic Imaging Chaya S. Moskowitz, PhD With thanks to Nancy Obuchowski Outline What is study design? Building blocks of imaging studies Strategies to improve study efficiency What

More information

95% 2.5% 2.5% +2SD 95% of data will 95% be within of data will 1.96 be within standard deviations 1.96 of sample mean

95% 2.5% 2.5% +2SD 95% of data will 95% be within of data will 1.96 be within standard deviations 1.96 of sample mean Efficient Clinical Trials John H. Powers, MD Senior Medical Scientist SAIC in support of Clinical Collaborative Research Branch NIAID/NIH Introduction Definitions what is a small clinical trial? Review

More information

Introduction to Statistics Design of Experiments

Introduction to Statistics Design of Experiments Introduction to Statistics Design of Experiments Instructor : Siana Halim TOPICS Controlled Experiments Observational Studies References Statistics,, David Freedman, Robert Pisani, Roger Purves 3 rd. Edition,

More information

DRAFT (Final) Concept Paper On choosing appropriate estimands and defining sensitivity analyses in confirmatory clinical trials

DRAFT (Final) Concept Paper On choosing appropriate estimands and defining sensitivity analyses in confirmatory clinical trials DRAFT (Final) Concept Paper On choosing appropriate estimands and defining sensitivity analyses in confirmatory clinical trials EFSPI Comments Page General Priority (H/M/L) Comment The concept to develop

More information

Complier Average Causal Effect (CACE)

Complier Average Causal Effect (CACE) Complier Average Causal Effect (CACE) Booil Jo Stanford University Methodological Advancement Meeting Innovative Directions in Estimating Impact Office of Planning, Research & Evaluation Administration

More information

Clinical Trials. Susan G. Fisher, Ph.D. Dept. of Clinical Sciences

Clinical Trials. Susan G. Fisher, Ph.D. Dept. of Clinical Sciences Clinical Trials Susan G. Fisher, Ph.D. Dept. of Clinical Sciences When to Do a RCT Exposure of interest is modifiable and individuals are willing to relinquish control Legitimate uncertainty exists about

More information

Villarreal Rm. 170 Handout (4.3)/(4.4) - 1 Designing Experiments I

Villarreal Rm. 170 Handout (4.3)/(4.4) - 1 Designing Experiments I Statistics and Probability B Ch. 4 Sample Surveys and Experiments Villarreal Rm. 170 Handout (4.3)/(4.4) - 1 Designing Experiments I Suppose we wanted to investigate if caffeine truly affects ones pulse

More information

Fixed Effect Combining

Fixed Effect Combining Meta-Analysis Workshop (part 2) Michael LaValley December 12 th 2014 Villanova University Fixed Effect Combining Each study i provides an effect size estimate d i of the population value For the inverse

More information

Previous Example. New. Tradition

Previous Example. New. Tradition Experimental Design Previous Example New Tradition Goal? New Tradition =? Challenges Internal validity How to guarantee what you have observed is true? External validity How to guarantee what you have

More information

Application of Randomization Techniques for an Unbiased Assessment of Outcome in Clinical Studies

Application of Randomization Techniques for an Unbiased Assessment of Outcome in Clinical Studies KP Suresh et al REVIEW ARTICLE 10.5005/jp-journals-10016-1137 Application of Randomization Techniques for an Unbiased Assessment of Outcome in Clinical Studies 1 KP Suresh, 2 Sri Yasaswini, 3 K Reshma

More information

AVOIDING BIAS AND RANDOM ERROR IN DATA ANALYSIS

AVOIDING BIAS AND RANDOM ERROR IN DATA ANALYSIS AVOIDING BIAS AND RANDOM ERROR IN DATA ANALYSIS Susan S. Ellenberg, Ph.D. Perelman School of Medicine University of Pennsylvania FDA Clinical Investigator Course Silver Spring, MD November 14, 2018 OVERVIEW

More information

Chapter 1 Data Types and Data Collection. Brian Habing Department of Statistics University of South Carolina. Outline

Chapter 1 Data Types and Data Collection. Brian Habing Department of Statistics University of South Carolina. Outline STAT 515 Statistical Methods I Chapter 1 Data Types and Data Collection Brian Habing Department of Statistics University of South Carolina Redistribution of these slides without permission is a violation

More information

Strategies for handling missing data in randomised trials

Strategies for handling missing data in randomised trials Strategies for handling missing data in randomised trials NIHR statistical meeting London, 13th February 2012 Ian White MRC Biostatistics Unit, Cambridge, UK Plan 1. Why do missing data matter? 2. Popular

More information

Challenges of Observational and Retrospective Studies

Challenges of Observational and Retrospective Studies Challenges of Observational and Retrospective Studies Kyoungmi Kim, Ph.D. March 8, 2017 This seminar is jointly supported by the following NIH-funded centers: Background There are several methods in which

More information

A (Constructive/Provocative) Critique of the ICH E9 Addendum

A (Constructive/Provocative) Critique of the ICH E9 Addendum A (Constructive/Provocative) Critique of the ICH E9 Addendum Daniel Scharfstein Johns Hopkins University dscharf@jhu.edu April 18, 2018 1 / 28 Disclosures Regularly consult with pharmaceutical and device

More information

Propensity Score Methods for Estimating Causality in the Absence of Random Assignment: Applications for Child Care Policy Research

Propensity Score Methods for Estimating Causality in the Absence of Random Assignment: Applications for Child Care Policy Research 2012 CCPRC Meeting Methodology Presession Workshop October 23, 2012, 2:00-5:00 p.m. Propensity Score Methods for Estimating Causality in the Absence of Random Assignment: Applications for Child Care Policy

More information

The Roles of Short Term Endpoints in. Clinical Trial Planning and Design

The Roles of Short Term Endpoints in. Clinical Trial Planning and Design The Roles of Short Term Endpoints in Clinical Trial Planning and Design Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj Roche, Welwyn Garden

More information

Recent developments for combining evidence within evidence streams: bias-adjusted meta-analysis

Recent developments for combining evidence within evidence streams: bias-adjusted meta-analysis EFSA/EBTC Colloquium, 25 October 2017 Recent developments for combining evidence within evidence streams: bias-adjusted meta-analysis Julian Higgins University of Bristol 1 Introduction to concepts Standard

More information

Revised Cochrane risk of bias tool for randomized trials (RoB 2.0) Additional considerations for cross-over trials

Revised Cochrane risk of bias tool for randomized trials (RoB 2.0) Additional considerations for cross-over trials Revised Cochrane risk of bias tool for randomized trials (RoB 2.0) Additional considerations for cross-over trials Edited by Julian PT Higgins on behalf of the RoB 2.0 working group on cross-over trials

More information

Revised Cochrane risk of bias tool for randomized trials (RoB 2.0)

Revised Cochrane risk of bias tool for randomized trials (RoB 2.0) Revised Cochrane risk of bias tool for randomized trials (RoB 2.0) Edited by Julian PT Higgins, Jelena Savović, Matthew J Page, Jonathan AC Sterne on behalf of the development group for RoB 2.0 20 th October

More information

Chapter 1 - Sampling and Experimental Design

Chapter 1 - Sampling and Experimental Design Chapter 1 - Sampling and Experimental Design Read sections 1.3-1.5 Sampling (1.3.3 and 1.4.2) Sampling Plans: methods of selecting individuals from a population. We are interested in sampling plans such

More information

Glossary From Running Randomized Evaluations: A Practical Guide, by Rachel Glennerster and Kudzai Takavarasha

Glossary From Running Randomized Evaluations: A Practical Guide, by Rachel Glennerster and Kudzai Takavarasha Glossary From Running Randomized Evaluations: A Practical Guide, by Rachel Glennerster and Kudzai Takavarasha attrition: When data are missing because we are unable to measure the outcomes of some of the

More information

Delfini Evidence Tool Kit

Delfini Evidence Tool Kit General 1. Who is sponsoring and funding the study? What are the affiliations of the authors? Study Design Assessment Internal Validity Assessment Considerations: This can be helpful information and is

More information

Risk of selection bias in randomised trials

Risk of selection bias in randomised trials Kahan et al. Trials (2015) 16:405 DOI 10.1186/s13063-015-0920-x TRIALS RESEARCH Risk of selection bias in randomised trials Brennan C. Kahan 1*, Sunita Rehal 2 and Suzie Cro 2 Open Access Abstract Background:

More information

ICH E9 (R1) Addendum on Estimands and Sensitivity Analysis

ICH E9 (R1) Addendum on Estimands and Sensitivity Analysis ICH E9 (R1) Addendum on Estimands and Sensitivity Analysis Rob Hemmings Mouna Akacha MHRA + ICH E9 (R1) Expert Working Group Novartis 1 Disclaimer (I) Not a statistical topic This impacts every clinical

More information

Treatment Adaptive Biased Coin Randomization: Generating Randomization Sequences in SAS

Treatment Adaptive Biased Coin Randomization: Generating Randomization Sequences in SAS Adaptive Biased Coin Randomization: OBJECTIVES use SAS code to generate randomization s based on the adaptive biased coin design (ABCD) must have approximate balance in treatment groups can be used to

More information

Mathematical-Statistical Modeling to Inform the Design of HIV Treatment Strategies and Clinical Trials

Mathematical-Statistical Modeling to Inform the Design of HIV Treatment Strategies and Clinical Trials Mathematical-Statistical Modeling to Inform the Design of HIV Treatment Strategies and Clinical Trials 2007 FDA/Industry Statistics Workshop Marie Davidian Department of Statistics North Carolina State

More information

INTERNAL VALIDITY, BIAS AND CONFOUNDING

INTERNAL VALIDITY, BIAS AND CONFOUNDING OCW Epidemiology and Biostatistics, 2010 J. Forrester, PhD Tufts University School of Medicine October 6, 2010 INTERNAL VALIDITY, BIAS AND CONFOUNDING Learning objectives for this session: 1) Understand

More information

Two-stage Methods to Implement and Analyze the Biomarker-guided Clinical Trail Designs in the Presence of Biomarker Misclassification

Two-stage Methods to Implement and Analyze the Biomarker-guided Clinical Trail Designs in the Presence of Biomarker Misclassification RESEARCH HIGHLIGHT Two-stage Methods to Implement and Analyze the Biomarker-guided Clinical Trail Designs in the Presence of Biomarker Misclassification Yong Zang 1, Beibei Guo 2 1 Department of Mathematical

More information

Controlled Trials. Spyros Kitsiou, PhD

Controlled Trials. Spyros Kitsiou, PhD Assessing Risk of Bias in Randomized Controlled Trials Spyros Kitsiou, PhD Assistant Professor Department of Biomedical and Health Information Sciences College of Applied Health Sciences University of

More information

Beyond the intention-to treat effect: Per-protocol effects in randomized trials

Beyond the intention-to treat effect: Per-protocol effects in randomized trials Beyond the intention-to treat effect: Per-protocol effects in randomized trials Miguel Hernán DEPARTMENTS OF EPIDEMIOLOGY AND BIOSTATISTICS Intention-to-treat analysis (estimator) estimates intention-to-treat

More information

Systematic Reviews and Meta- Analysis in Kidney Transplantation

Systematic Reviews and Meta- Analysis in Kidney Transplantation Systematic Reviews and Meta- Analysis in Kidney Transplantation Greg Knoll MD MSc Associate Professor of Medicine Medical Director, Kidney Transplantation University of Ottawa and The Ottawa Hospital KRESCENT

More information

Variable Data univariate data set bivariate data set multivariate data set categorical qualitative numerical quantitative

Variable Data univariate data set bivariate data set multivariate data set categorical qualitative numerical quantitative The Data Analysis Process and Collecting Data Sensibly Important Terms Variable A variable is any characteristic whose value may change from one individual to another Examples: Brand of television Height

More information

CRITICAL APPRAISAL OF MEDICAL LITERATURE. Samuel Iff ISPM Bern

CRITICAL APPRAISAL OF MEDICAL LITERATURE. Samuel Iff ISPM Bern CRITICAL APPRAISAL OF MEDICAL LITERATURE Samuel Iff ISPM Bern siff@ispm.unibe.ch Contents Study designs Asking good questions Pitfalls in clinical studies How to assess validity (RCT) Conclusion Step-by-step

More information

Sampling Controlled experiments Summary. Study design. Patrick Breheny. January 22. Patrick Breheny Introduction to Biostatistics (BIOS 4120) 1/34

Sampling Controlled experiments Summary. Study design. Patrick Breheny. January 22. Patrick Breheny Introduction to Biostatistics (BIOS 4120) 1/34 Sampling Study design Patrick Breheny January 22 Patrick Breheny to Biostatistics (BIOS 4120) 1/34 Sampling Sampling in the ideal world The 1936 Presidential Election Pharmaceutical trials and children

More information

Chapter 23. Inference About Means. Copyright 2010 Pearson Education, Inc.

Chapter 23. Inference About Means. Copyright 2010 Pearson Education, Inc. Chapter 23 Inference About Means Copyright 2010 Pearson Education, Inc. Getting Started Now that we know how to create confidence intervals and test hypotheses about proportions, it d be nice to be able

More information

CHAPTER 2 EVALUATING NUTRITION INFORMATION OVERVIEW

CHAPTER 2 EVALUATING NUTRITION INFORMATION OVERVIEW CHAPTER 2 EVALUATING NUTRITION INFORMATION OVERVIEW Chapter 2 focuses on the generation and dissemination of nutrition knowledge. The scientific method is presented as the basis for nutrition research,

More information

Math 1680 Class Notes. Chapters: 1, 2, 3, 4, 5, 6

Math 1680 Class Notes. Chapters: 1, 2, 3, 4, 5, 6 Math 1680 Class Notes Chapters: 1, 2, 3, 4, 5, 6 Chapter 1. Controlled Experiments Salk vaccine field trial: a randomized controlled double-blind design 1. Suppose they gave the vaccine to everybody, and

More information

Appraising the Literature Overview of Study Designs

Appraising the Literature Overview of Study Designs Chapter 5 Appraising the Literature Overview of Study Designs Barbara M. Sullivan, PhD Department of Research, NUHS Jerrilyn A. Cambron, PhD, DC Department of Researach, NUHS EBP@NUHS Ch 5 - Overview of

More information

Higher Psychology RESEARCH REVISION

Higher Psychology RESEARCH REVISION Higher Psychology RESEARCH REVISION 1 The biggest change from the old Higher course (up to 2014) is the possibility of an analysis and evaluation question (8-10) marks asking you to comment on aspects

More information

Missing data in clinical trials: making the best of what we haven t got.

Missing data in clinical trials: making the best of what we haven t got. Missing data in clinical trials: making the best of what we haven t got. Royal Statistical Society Professional Statisticians Forum Presentation by Michael O Kelly, Senior Statistical Director, IQVIA Copyright

More information

Section 1: The Science of Clinical Investigation

Section 1: The Science of Clinical Investigation INTRODUCTION TO CLINICAL RESEARCH Scientific Concepts for Clinical Research Scott L. Zeger, Ph.D. July 14, 2014 Section 1: The Science of Clinical Investigation 1. Platonic model: science as the search

More information

Outcomes research is critical in the evidence-based

Outcomes research is critical in the evidence-based Journal of Athletic Training 2008;43(2):215 221 g by the National Athletic Trainers Association, Inc www.nata.org/jat communications Issues in Outcomes Research: An Overview of Randomization Techniques

More information

Glossary. Ó 2010 John Wiley & Sons, Ltd

Glossary. Ó 2010 John Wiley & Sons, Ltd Glossary The majority of the definitions within this glossary are based on, but are only a selection from, the comprehensive list provided by Day (2007) in the Dictionary of Clinical Trials. We have added

More information

Statistical Challenges for Novel Technologies. Roseann M. White, MA Director of Pragmatic Clinical Trial Statistics Duke Clinical Research Institute

Statistical Challenges for Novel Technologies. Roseann M. White, MA Director of Pragmatic Clinical Trial Statistics Duke Clinical Research Institute Statistical Challenges for Novel Technologies Roseann M. White, MA Director of Pragmatic Clinical Trial Statistics Duke Clinical Research Institute ISCTM 2016 Autumn Conference, Philadelphia, PA 27 September

More information

Design for Targeted Therapies: Statistical Considerations

Design for Targeted Therapies: Statistical Considerations Design for Targeted Therapies: Statistical Considerations J. Jack Lee, Ph.D. Department of Biostatistics University of Texas M. D. Anderson Cancer Center Outline Premise General Review of Statistical Designs

More information

Lecture Outline. Biost 590: Statistical Consulting. Stages of Scientific Studies. Scientific Method

Lecture Outline. Biost 590: Statistical Consulting. Stages of Scientific Studies. Scientific Method Biost 590: Statistical Consulting Statistical Classification of Scientific Studies; Approach to Consulting Lecture Outline Statistical Classification of Scientific Studies Statistical Tasks Approach to

More information

The random variable must be a numeric measure resulting from the outcome of a random experiment.

The random variable must be a numeric measure resulting from the outcome of a random experiment. Now we will define, discuss, and apply random variables. This will utilize and expand upon what we have already learned about probability and will be the foundation of the bridge between probability and

More information

Chapter 19. Confidence Intervals for Proportions. Copyright 2010 Pearson Education, Inc.

Chapter 19. Confidence Intervals for Proportions. Copyright 2010 Pearson Education, Inc. Chapter 19 Confidence Intervals for Proportions Copyright 2010 Pearson Education, Inc. Standard Error Both of the sampling distributions we ve looked at are Normal. For proportions For means SD pˆ pq n

More information

Introduction & Basics

Introduction & Basics CHAPTER 1 Introduction & Basics 1.1 Statistics the Field... 1 1.2 Probability Distributions... 4 1.3 Study Design Features... 9 1.4 Descriptive Statistics... 13 1.5 Inferential Statistics... 16 1.6 Summary...

More information

Using Statistical Principles to Implement FDA Guidance on Cardiovascular Risk Assessment for Diabetes Drugs

Using Statistical Principles to Implement FDA Guidance on Cardiovascular Risk Assessment for Diabetes Drugs Using Statistical Principles to Implement FDA Guidance on Cardiovascular Risk Assessment for Diabetes Drugs David Manner, Brenda Crowe and Linda Shurzinske BASS XVI November 9-13, 2009 Acknowledgements

More information

Randomized Clinical Trials

Randomized Clinical Trials Randomized Clinical Trials p. 1/42 Randomized Clinical Trials Hematology/Oncology Lecture Series Elizabeth G. Hill, PhD Associate Professor of Biostatistics 17 November 2011 Randomized Clinical Trials

More information

Intervention vs. Observational Trials:

Intervention vs. Observational Trials: Intervention vs. Observational Trials: A Brief Introduction Introduction Just like an architect translates a vision for a building into blueprints, so an investigator translates their research idea into

More information

Chapter 13. Experiments and Observational Studies. Copyright 2012, 2008, 2005 Pearson Education, Inc.

Chapter 13. Experiments and Observational Studies. Copyright 2012, 2008, 2005 Pearson Education, Inc. Chapter 13 Experiments and Observational Studies Copyright 2012, 2008, 2005 Pearson Education, Inc. Observational Studies In an observational study, researchers don t assign choices; they simply observe

More information

You can t fix by analysis what you bungled by design. Fancy analysis can t fix a poorly designed study.

You can t fix by analysis what you bungled by design. Fancy analysis can t fix a poorly designed study. You can t fix by analysis what you bungled by design. Light, Singer and Willett Or, not as catchy but perhaps more accurate: Fancy analysis can t fix a poorly designed study. Producing Data The Role of

More information

Analysis Plans in Economics

Analysis Plans in Economics MIT December 2012 Where did this come from... for me. Where did this come from... for me. High school internship in a medical lab doing research on anti-stroke drugs Where did this come from... for me.

More information

Vocabulary. Bias. Blinding. Block. Cluster sample

Vocabulary. Bias. Blinding. Block. Cluster sample Bias Blinding Block Census Cluster sample Confounding Control group Convenience sample Designs Experiment Experimental units Factor Level Any systematic failure of a sampling method to represent its population

More information

Special Features of Randomized Controlled Trials

Special Features of Randomized Controlled Trials Special Features of Randomized Controlled Trials Bangkok 2006 Kenneth F. Schulz, PhD, MBA Critical Methodological Elements in RCTs Randomization Avoiding and handling exclusions after trial entry Blinding

More information

NEED A SAMPLE SIZE? How to work with your friendly biostatistician!!!

NEED A SAMPLE SIZE? How to work with your friendly biostatistician!!! NEED A SAMPLE SIZE? How to work with your friendly biostatistician!!! BERD Pizza & Pilots November 18, 2013 Emily Van Meter, PhD Assistant Professor Division of Cancer Biostatistics Overview Why do we

More information

Module 5. The Epidemiological Basis of Randomised Controlled Trials. Landon Myer School of Public Health & Family Medicine, University of Cape Town

Module 5. The Epidemiological Basis of Randomised Controlled Trials. Landon Myer School of Public Health & Family Medicine, University of Cape Town Module 5 The Epidemiological Basis of Randomised Controlled Trials Landon Myer School of Public Health & Family Medicine, University of Cape Town Introduction The Randomised Controlled Trial (RCT) is the

More information

Introduction; Study design

Introduction; Study design ; Study design Patrick Breheny January 12 Patrick Breheny STA 580: Biostatistics I 1/43 What is statistics? What is biostatistics, and why is it important? The statistical framework Statistics is the science

More information

Abdul Latif Jameel Poverty Action Lab Executive Training: Evaluating Social Programs Spring 2009

Abdul Latif Jameel Poverty Action Lab Executive Training: Evaluating Social Programs Spring 2009 MIT OpenCourseWare http://ocw.mit.edu Abdul Latif Jameel Poverty Action Lab Executive Training: Evaluating Social Programs Spring 2009 For information about citing these materials or our Terms of Use,

More information

NOVEL BIOMARKERS PERSPECTIVES ON DISCOVERY AND DEVELOPMENT. Winton Gibbons Consulting

NOVEL BIOMARKERS PERSPECTIVES ON DISCOVERY AND DEVELOPMENT. Winton Gibbons Consulting NOVEL BIOMARKERS PERSPECTIVES ON DISCOVERY AND DEVELOPMENT Winton Gibbons Consulting www.wintongibbons.com NOVEL BIOMARKERS PERSPECTIVES ON DISCOVERY AND DEVELOPMENT This whitepaper is decidedly focused

More information

Safeguarding public health Subgroup Analyses: Important, Infuriating and Intractable

Safeguarding public health Subgroup Analyses: Important, Infuriating and Intractable Safeguarding public health Subgroup Analyses: Important, Infuriating and Intractable The views expressed herein are not necessarily those of MHRA, EMA, EMA committees or their working parties. Rob Hemmings

More information

I. Introduction and Data Collection B. Sampling. 1. Bias. In this section Bias Random Sampling Sampling Error

I. Introduction and Data Collection B. Sampling. 1. Bias. In this section Bias Random Sampling Sampling Error I. Introduction and Data Collection B. Sampling In this section Bias Random Sampling Sampling Error 1. Bias Bias a prejudice in one direction (this occurs when the sample is selected in such a way that

More information

Incorporating Clinical Information into the Label

Incorporating Clinical Information into the Label ECC Population Health Group LLC expertise-driven consulting in global maternal-child health & pharmacoepidemiology Incorporating Clinical Information into the Label Labels without Categories: A Workshop

More information